Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 282 results for back pain

  1. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA926

  2. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  3. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    did not improve sciatica symptoms, and oral corticosteroids did not improve pain or function, but may have an impact on quality of life....

    Research recommendation
    Published
    22 January 2021

  4. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    did not improve sciatica symptoms, and oral corticosteroids did not improve pain or function, but may have an impact on quality of life....

    Research recommendation
    Published
    26 October 2020

  5. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  6. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    We have moved health technology evaluation 16 to become HealthTech guidance 712. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)

    We have moved interventional procedures guidance 739 to become HealthTech guidance 641. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)

    We have moved interventional procedures guidance 543 to become HealthTech guidance 397. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

    Medtech innovation briefing
    Published
    15 December 2020

  10. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

    Medtech innovation briefing
    Published
    7 March 2017

  11. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    Source guidance details Comes from guidance Low back pain and sciatica in over 16s: assessment and management Number NG59

    Research recommendation
    Published
    26 October 2020

  12. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

    NICE guideline
    Published
    18 November 2020
    View recommendations

    Sections for NG185

  13. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (IPG545)

    We have moved interventional procedures guidance 545 to become HealthTech guidance 399. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Medicines management in care homes (QS85)

    This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    25 March 2015
    View quality statements

    Sections for QS85

  15. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

    Medtech innovation briefing
    Published
    2 March 2015